LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

2.43 -2.41

Overview

Share price change

24h

Current

Min

2.42

Max

2.57

Key metrics

By Trading Economics

Income

-17M

-70M

Sales

547K

47M

Profit margin

-147.345

Employees

560

EBITDA

-17M

-66M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+86.06% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

133M

886M

Previous open

4.84

Previous close

2.43

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

8 Sept 2025, 23:59 UTC

Acquisitions, Mergers, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 Sept 2025, 22:02 UTC

Major Market Movers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 Sept 2025, 17:01 UTC

Major Market Movers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 Sept 2025, 17:01 UTC

Major Market Movers

Tron Shares Rise After New Investment From Bravemorning

8 Sept 2025, 16:14 UTC

Major Market Movers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 Sept 2025, 16:13 UTC

Major Market Movers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 Sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 Sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 Sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 Sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 Sept 2025, 21:47 UTC

Major Market Movers

Microsoft Signs $17.4B AI Deal With Nebius

8 Sept 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 Sept 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 Sept 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 Sept 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 Sept 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 Sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 Sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 Sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 Sept 2025, 16:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 Sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 Sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 16:16 UTC

Earnings

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 Sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

86.06% upside

12 Months Forecast

Average 4.67 USD  86.06%

High 5 USD

Low 4 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat